Citizens has reaffirmed its 'Market Outperform' rating on Waystar, the healthcare payments technology firm, underscoring sustained analyst confidence in the company's growth trajectory. The rating, maintained as of 20 July 2026, reflects expectations that Waystar will continue to outperform the broader market, despite recent volatility in the technology and healthcare sectors.
Waystar, which provides cloud-based payment and revenue cycle management software for healthcare providers, has been a notable player in the digital health space. The reaffirmation from Citizens comes as the FTSE 100 edged 0.3% lower to 8,210 points on Monday, weighed down by cautious sentiment ahead of key US earnings reports. The FTSE 250 slipped 0.1% to 20,540, with healthcare and tech stocks mixed.
For UK investors, the rating holds significance as many hold US-listed equities through pensions or ISAs. Waystar is not directly listed in London, but its performance influences global healthcare and tech exchange-traded funds (ETFs) popular with British savers. Analysts note that a 'Market Outperform' rating typically suggests the stock could deliver above-average returns relative to its sector peers.
“The reaffirmation signals that Citizens sees Waystar's fundamentals as strong, particularly given the ongoing digitisation of healthcare payments,” said a market strategist at a London-based brokerage, speaking on condition of anonymity. “For UK pension holders with diversified portfolios, such ratings provide a useful benchmark for assessing US exposure.”
The broader context includes rising interest rates in the US and UK, which have pressured growth stocks. However, healthcare technology has proven relatively resilient due to structural demand. Waystar's focus on reducing administrative costs for hospitals aligns with cost-saving trends across the NHS and private healthcare systems in the UK.